The MUFFIN-PTS Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

March 30, 2024

Study Completion Date

May 30, 2024

Conditions
Post-Thrombotic Syndrome
Interventions
DRUG

Micronized Purified Flavonoid Fraction

After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment

DRUG

Placebo

After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment

Trial Locations (7)

Unknown

Vancouver General Hospital, Vancouver

B3H 3A7

Queen Elizabeth II Health Sciences Centre, Halifax

L8L 2X2

Hamilton General Hospital, Hamilton

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 1Z5

Toronto General Hospital, Toronto

H3T 1E2

Sir Mortimer B. Davis - Jewish General Hospital, Montreal

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER